These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19013229)

  • 41. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity.
    Aye IL; Waddell BJ; Mark PJ; Keelan JA
    Biochim Biophys Acta; 2010 Sep; 1801(9):1013-24. PubMed ID: 20570635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists.
    Wittgen HG; Greupink R; van den Heuvel JJ; van den Broek PH; Dinter-Heidorn H; Koenderink JB; Russel FG
    Mol Pharm; 2012 May; 9(5):1351-60. PubMed ID: 22428727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line.
    Rubinchik-Stern M; Shmuel M; Eyal S
    Epilepsia; 2015 Jul; 56(7):1023-32. PubMed ID: 26032972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
    Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines.
    Cuestas ML; Sosnik A; Mathet VL
    Mol Pharm; 2011 Aug; 8(4):1152-64. PubMed ID: 21591727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P; Surowiak P; Lage H
    Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
    Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
    Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
    Takeuchi R; Shinozaki K; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):68-74. PubMed ID: 26467765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
    Choi MK; Song IS
    J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.